A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women.
🦱 탈모
🔵 RCT
4/5 보강
TL;DR
Once-daily 5% MTF is noninferior and as effective for stimulating hair growth as twice-daily 2% MTS in women with androgenetic alopecia and is associated with several aesthetic and practical advantages.
📑 코퍼스 인용 관계
· 인용됨 38
📑 인용한 논문 (6) ▾
- Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation… American journal of clinical dermatology · 2026
- Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral … Frontiers in pharmacology · 2025
- Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%… Dermatology practical & conceptual · 2025
- Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for… Journal of clinical medicine · 2025
- Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal w… International journal of women's dermatology · 2025
- Topical minoxidil effectiveness in enhancing facial aesthetics: A systematic review and me… Journal of family medicine and primary care · 2025
연도별 인용 (2012–2026) · 합계 165
OpenAlex 토픽 ·
Hair Growth and Disorders
Dermatology and Skin Diseases
Acne and Rosacea Treatments and Effects
Abstract 🌐 Abstract
[BACKGROUND] Although twice-daily application of propylene glycol-containing 2% minoxidil topical solution (MTS) stimulates new hair growth, higher concentrations of minoxidil in a once-daily, propylene glycol-free formulation may improve efficacy and reduce unpleasant side effects.
[OBJECTIVE] We sought to compare the efficacy, safety, and acceptability and to show noninferiority of once-daily 5% minoxidil topical foam (MTF) with twice-daily 2% MTS in women with androgenetic alopecia.
[METHODS] A total of 113 women with androgenetic alopecia were randomized to 24 weeks of treatment with 5% MTF or 2% MTS. The primary efficacy parameter was change from baseline in nonvellus target area hair count at week 24. Secondary end points included change in nonvellus target area hair width, overall efficacy by global photographic review as assessed by treatment-blinded evaluators and the subject herself, adverse events, and participants' assessment of product aesthetics.
[RESULTS] After 24 weeks, women randomized to 5% MTF once daily showed noninferior target area hair count and target area hair width and experienced greater, but nonsignificant, improvements in target area hair count, target area hair width, and overall efficacy by global photographic review than those randomized to 2% MTS used twice daily. 5% MTF was significantly superior to 2% MTS in participants' agreement with "the treatment does not interfere with styling my hair" (P = .002). Women randomized to 5% MTF experienced significantly lower rates of local intolerance (P = .046) especially in pruritus and dandruff compared with 2% MTS.
[LIMITATION] Because of differences in the formulations tested, study participants were not blinded to treatment.
[CONCLUSIONS] Once-daily 5% MTF is noninferior and as effective for stimulating hair growth as twice-daily 2% MTS in women with androgenetic alopecia and is associated with several aesthetic and practical advantages.
[OBJECTIVE] We sought to compare the efficacy, safety, and acceptability and to show noninferiority of once-daily 5% minoxidil topical foam (MTF) with twice-daily 2% MTS in women with androgenetic alopecia.
[METHODS] A total of 113 women with androgenetic alopecia were randomized to 24 weeks of treatment with 5% MTF or 2% MTS. The primary efficacy parameter was change from baseline in nonvellus target area hair count at week 24. Secondary end points included change in nonvellus target area hair width, overall efficacy by global photographic review as assessed by treatment-blinded evaluators and the subject herself, adverse events, and participants' assessment of product aesthetics.
[RESULTS] After 24 weeks, women randomized to 5% MTF once daily showed noninferior target area hair count and target area hair width and experienced greater, but nonsignificant, improvements in target area hair count, target area hair width, and overall efficacy by global photographic review than those randomized to 2% MTS used twice daily. 5% MTF was significantly superior to 2% MTS in participants' agreement with "the treatment does not interfere with styling my hair" (P = .002). Women randomized to 5% MTF experienced significantly lower rates of local intolerance (P = .046) especially in pruritus and dandruff compared with 2% MTS.
[LIMITATION] Because of differences in the formulations tested, study participants were not blinded to treatment.
[CONCLUSIONS] Once-daily 5% MTF is noninferior and as effective for stimulating hair growth as twice-daily 2% MTS in women with androgenetic alopecia and is associated with several aesthetic and practical advantages.
- p-value P = .002
- p-value P = .046
Once-daily 5% MTF is noninferior and as effective for stimulating hair growth as twice-daily 2% MTS in women with androgenetic alopecia and is associated with several aesthetic and practical advantage
APA 7
Blume-Peytavi, U., Hillmann, K., Dietz, E., Canfield, D., & N, G. B. (2011). A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women.. Journal of the American Academy of Dermatology, 65(6), 1126-1134.e2. https://doi.org/10.1016/j.jaad.2010.09.724
Vancouver
Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, N GB. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Jour. Amer. Acad. Derm.. 2011;65(6):1126-1134.e2. doi:10.1016/j.jaad.2010.09.724
AMA 11
Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, N GB. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Jour. Amer. Acad. Derm.. 2011;65(6):1126-1134.e2. doi:10.1016/j.jaad.2010.09.724
Chicago
Blume-Peytavi, U., Hillmann, K., Dietz, E., Canfield, D., and N, G. B.. 2011. "A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women." Journal of the American Academy of Dermatology 65 (6): 1126-1134.e2. https://doi.org/10.1016/j.jaad.2010.09.724
MLA 9
Blume-Peytavi, U., et al. "A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women." Journal of the American Academy of Dermatology, vol. 65, no. 6, 2011, pp. 1126-1134.e2. doi:10.1016/j.jaad.2010.09.724.
PMID
21700360 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 7/8 (88%)
· 참조 0편 · 후속 7편
이 논문을 인용한 후속 연구 20
- Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considera…
- Minoxidil and its use in hair disorders: a review.
- Androgenetic Alopecia: An Update of Treatment Options.
- Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review.
- Complementary and Alternative Treatments for Alopecia: A Comprehensive Review.
- Alopecia Areata: An Updated Review for 2023.
- Interventions for female pattern hair loss.
- Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alo…
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Dis…
- Female Pattern Hair Loss-An Update.
- Female-pattern hair loss: therapeutic update.
- Comparison of 5% minoxidil lotion monotherapy versus its combination with autologous platelet rich p…
- Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Mi…
- Short-Term Efficacy of Autologous Cellular Micrografts in Male and Female Androgenetic Alopecia: A R…
- Intermediate Hair Follicles from Patients with Female Pattern Hair Loss Are Associated with Nutrient…
- Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil…
- Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia:…
- Bitemporal Scalp Hair Loss: Differential Diagnosis of Nonscarring and Scarring Conditions.
- Comparing the Effects of Zinc Sulfate, Calcium Pantothenate, Their Combination and Minoxidil Solutio…
- Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug …
같은 제1저자의 인용 많은 논문 (5)
- Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women.
- Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study.
- Follicular and percutaneous penetration pathways of topically applied minoxidil foam.
- Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo-controlled, double-blind, noninferiority study.
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 피나스테리드가 전립선암 발생에 미치는 영향.
- COVID-19의 50가지 이상의 장기 후유증: 체계적 문헌고찰 및 메타분석.
- 양성 전립선 비대증의 임상적 진행에 대한 doxazosin, finasteride 및 병용 요법의 장기 효과.
- 양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
- 원형 탈모.